Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: BostonGene and Exigent Genomic INsight Study
Clinical trial update indicates that the BostonGene-Exigent Genomic INsight study is currently recruiting participants across indications in…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating the combination of Vebreltinib and Osimertinib in advanced non-small cell lung cancer with an EGFR L858R m…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) [Phase 2]
Phase 2 DENIVOS trial evaluating the combination of denosumab and nivolumab as second-line therapy for stage IV non-small cell lung cancer w…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. [NA]
This clinical trial update describes an education intervention aimed at helping patients manage rash associated with epidermal growth factor…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients [Phase 3]
Durvalumab was studied as consolidation therapy in non-small cell lung cancer in a Phase 3 trial, with results posted in 2025. The results w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: Orlistat Overcoming Third-generation EGFR-TKI Resistance [Phase 2]
Phase 2 clinical trial evaluating whether adding orlistat can overcome resistance to osimertinib in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation [Phase 2]
Phase 2 trial of osimertinib for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion has completed with po…
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers [Phase 2]
A Phase 2 trial of intensified chemo-immuno-radiotherapy with durvalumab for Stage III non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease [NA]
This entry describes a recruiting clinical trial evaluating CSF analysis in patients with EGFR-mutant non-small cell lung cancer and leptome…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2 [Phase 2]
Pembrolizumab was studied in a Phase 2 trial in non-small cell lung cancer patients with performance status 2; the study has completed and r…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing tislelizumab to docetaxel in second- or third-line non-small cell lung cancer has posted results.
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations [Phase 1]
Phase 1 study of BLU-451 for advanced cancers with EGFR Exon 20 insertion mutations has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC [Phase 1]
The SYMPHONY Phase 1/2 trial targeting EGFR resistance mechanisms in non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer [Phase 1]
Seagen's SEA-TGT (SGN-TGT) Phase 1 safety study in advanced cancers has been terminated. The study enrolled patients across multiple cancer …
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Study of SGN-ALPV in Advanced Solid Tumors [Phase 1]
Seagen's Phase 1 study of SGN-ALPV in advanced solid tumors has been terminated; the trial evaluated multiple cancers including ovarian, end…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: A Study of SGN-STNV in Advanced Solid Tumors [Phase 1]
Seagen's Phase 1 study of SGN-STNV in advanced solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC [Phase 1]
Phase 1 study evaluating toripalimab with anlotinib and SBRT for untreated brain metastases in gene-negative non-small cell lung cancer has …
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer [Phase 1]
A Phase 1 trial of Biomea Fusion's covalent menin inhibitor BMF-219 in KRAS-driven non-small cell lung cancer, pancreatic cancer, and colore…
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue [NA]
A Mayo Clinic-led study evaluating remote monitoring with health coaching for lifestyle changes to address fatigue in patients with advanced…
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) [Phase 3]
Phase 3 trial evaluating pembrolizumab with maintenance olaparib or maintenance pemetrexed as first-line therapy in metastatic nonsquamous n…
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating UCPVax in combination with nivolumab as second-line therapy for advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites [NA]
The trial investigates using liquid biopsy to shorten time to treatment for advanced non-small cell lung cancer diagnosed at outside sites. …
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation [Phase 2]
Phase 2 trial evaluating Osimertinib in EGFR-mutant non-small cell lung cancer with brain or leptomeningeal metastases has completed. The st…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer [Phase 1]
Phase 1 study evaluating safety and immunogenicity of the live-attenuated Listeria immunotherapy JNJ-64041757 in non-small cell lung cancer …
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers [Phase 1]
Phase 1 study of cosibelimab (CK-301) as a single-agent therapy in adults with advanced cancers; the trial status is active but not recruiti…